Parexel already has offices in Tokyo and Kobe.
Parexel now has 18 offices throughout important biopharmaceutical centers in the Asia/Pacific region, including Japan, Australia, China, India, Indonesia, Malaysia, the Philippines, Singapore, South Korea, Taiwan, and Thailand.
Parexel chairman and CEO Josef von Rickenbac said that the opening of the office in Nagoya builds on established presence and long-term, ongoing commitment to Japan.
“Parexel’s expansion in Japan allows us to further assist locally-based clients with regional and global market access opportunities,” Rickenbac said.
“We are also supporting Japan-based biopharmaceutical companies with simultaneous global clinical studies across a broad range of therapeutic areas, and providing eClinical solutions to accelerate the clinical development process.”